<DOC>
	<DOCNO>NCT01298518</DOCNO>
	<brief_summary>PF-04620110 novel compound propose treatment Type 2 diabetes mellitus . The primary purpose trial evaluate safety tolerability , pharmacodynamics , multiple oral dos PF-04620110 T2DM patient .</brief_summary>
	<brief_title>A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male and/or female subject age 18 60 year ; Body Mass Index ( BMI ) &gt; 25.0 kg/m2 &lt; 40 kg/m2 ; Subjects must historical diagnosis T2DM accordance ADA guideline ; Subjects welltolerated stable dos metformin Recent evidence ( 6 month prior screen ) history unstable major organ disease ; Diagnosis Type 1 diabetes mellitus ; Current medical history myocardial infarction , unstable angina , history stroke ( include TIA ) within 6 month prior Screening ; Treatment thiazolidinediones ( TZDs ) , subcutaneously administer antidiabetic agent ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>multiple dose study type 2 diabetes patient</keyword>
</DOC>